Middle East And Africa Hepatitis Delta Virus Hdv Infection Market
Taille du marché en milliards USD
TCAC :
% 
 Période de prévision |
2024 –2031 |
 Taille du marché (année de référence) |
USD 10.37 Million |
 Taille du marché (année de prévision) |
USD 14.65 Million |
 TCAC |
% |
| Principaux acteurs du marché |
>Marché de l'infection par le virus de l'hépatite Delta (VHD) au Moyen-Orient et en Afrique, par type (hépatite D aiguë et hépatite D chronique), traitement (chirurgie ( transplantation hépatique ) et médicaments), type de médicament (de marque et générique), voie d'administration (orale et parentérale), groupe d'âge (adultes, gériatrique et pédiatrique), sexe (femme et homme), transmission (aiguilles contaminées, exposition au sang infecté, transfusion de produits sanguins et plasmatiques, et autres), utilisateur final (hôpitaux, cliniques spécialisées, établissements de soins à domicile, instituts de recherche et centres universitaires, centres de chirurgie ambulatoire, et autres), canal de distribution (appel d'offres direct, ventes au détail, et autres) - Tendances et prévisions de l'industrie jusqu'en 2031
Analyse et perspectives du marché de l'infection par le virus de l'hépatite delta (VHD) au Moyen-Orient et en Afrique
La prévalence croissante de l'hépatite, en particulier de l'hépatite B, influence considérablement le marché de l'infection par le virus de l'hépatite delta (VHD) au Moyen-Orient et en Afrique. L'hépatite D est une infection du foie causée par le virus de l'hépatite D (VHD), qui nécessite la présence du virus de l'hépatite B (VHB) pour se répliquer. À mesure que les infections par l'hépatite B augmentent au niveau régional, le nombre de personnes susceptibles d'être infectées par le VHD augmente également. Ce nombre croissant de personnes infectées par le VHB crée une population cible plus large pour le VHD, ce qui stimule la demande de solutions diagnostiques et thérapeutiques spécifiques au VHD.
Data Bridge Market Research analyse que le marché de l'infection par le virus de l'hépatite Delta (HDV) au Moyen-Orient et en Afrique devrait atteindre 14,65 millions USD d'ici 2031, contre 10,37 millions USD en 2023, avec un TCAC de 4,6 % au cours de la période de prévision de 2024 à 2031.
|
Rapport métrique |
Détails |
|
Période de prévision |
2024 à 2031 |
|
Année de base |
2023 |
|
Années historiques |
2022 (personnalisable pour 2016-2021) |
|
Unités quantitatives |
Chiffre d'affaires en millions USD |
|
Segments couverts |
Type (hépatite D aiguë et hépatite D chronique), traitement (chirurgie (transplantation hépatique) et médicaments), type de médicament (de marque et générique), voie d'administration (orale et parentérale), groupe d'âge (adultes, gériatriques et pédiatriques), sexe (femme et homme), transmission (aiguilles contaminées, exposition au sang infecté, transfusion de produits sanguins et plasmatiques, et autres), utilisateur final (hôpitaux, cliniques spécialisées, établissements de soins à domicile, instituts de recherche et centres universitaires, centres de chirurgie ambulatoire , et autres), canal de distribution (appel d'offres direct, ventes au détail, et autres) |
|
Pays couverts |
Afrique du Sud, Arabie saoudite, Émirats arabes unis, Égypte, Bahreïn, Koweït, Oman, Qatar et reste du Moyen-Orient et de l'Afrique |
|
Acteurs du marché couverts |
GILEAD SCIENCES, INC., GENENTECH, INC., ALNYLAM PHARMACEUTICALS, INC., ASSEMBLY BIOSCIENCES, INC., EIGER BIOPHARMACEUTICALS, GLOBEIMMUNE INC., HUAHUI HEALTH LTD., JOHNSON & JOHNSON SERVICES, INC., PHARMAESSENTIA CORPORATION, REPLICOR, VIR BIOTECHNOLOGY, INC. |
Définition du marché
Hepatitis Delta (HDV) infection is a rare but severe form of viral hepatitis that occurs when the Hepatitis Delta Virus (HDV) infects a liver already infected with Hepatitis B Virus (HBV). HDV is a defective virus that requires HBV to replicate and produce new viral particles, and it is characterized by its ability to rapidly cause liver disease, including acute hepatitis, liver failure, and even death. The coinfection of HBV and HDV leads to a more severe and rapid progression of liver disease compared to HBV infection alone, and it is often associated with higher levels of liver inflammation and fibrosis.
Middle East and Africa Hepatitis Delta Virus (HDV) Infection Market Dynamics
This section deals with understanding the market drivers, opportunities, restraints, and challenges. All of this is discussed in detail below:
Drivers
- Growing Prevalence of Hepatitis
The growing prevalence of hepatitis, particularly hepatitis B, is significantly influencing the Middle East and Africa Hepatitis Delta Virus (HDV) infection market. Hepatitis D is a liver infection caused by the Hepatitis D Virus (HDV), which requires the presence of the Hepatitis B Virus (HBV) to replicate. As hepatitis B infections increased regionally, the number of individuals susceptible to HDV infection also rises. This growing pool of HBV-infected individuals creates a larger target population for HDV, thus driving demand for diagnostic and therapeutic solutions specific to HDV.
- Increase in Healthcare Expenditure
The increase in healthcare expenditure has a significant impact on the growth of the Middle East and Africa Hepatitis Delta Virus (HDV) infection market by facilitating more substantial investment in diagnostic technologies and treatment options. As healthcare budgets expand, governments and healthcare organizations are able to allocate more resources towards advanced diagnostic tools for HDV. This investment leads to the development and deployment of more sensitive and accurate testing methods, which enhances early detection rates and drives up demand for diagnostic services. The improved availability of high-quality diagnostic tests contributes directly to market growth by increasing the overall testing and screening activities. Moreover, higher healthcare expenditure often translates into better access to and affordability of treatment options for HDV. As funding increases, there is greater potential for the development and distribution of innovative antiviral therapies and other medical interventions. This expanded access to effective treatments not only improves patient outcomes but also stimulates market growth by creating a more extensive patient base seeking treatment options. Enhanced therapeutic options can lead to better disease management and higher rates of treatment adherence, further boosting demand within the HDV infection market.
Opportunity
- Rising Innovative Drug Development
Pipeline therapies like JNJ-73763989 and Peginterferon Lambda are creating new opportunities for pharmaceutical companies to address the substantial unmet need for effective treatments in this space. JNJ-73763989 is a ground-breaking therapy designed to inhibit the replication of HDV by targeting essential components of the viral life cycle, offering a more precise and potentially effective approach compared to existing treatments. On the other hand, Peginterferon Lambda, a novel form of interferon therapy, is being evaluated for its ability to provide antiviral effects while minimizing the side effects traditionally associated with interferon-based treatments. Its targeted mechanism of action has the potential to improve patient outcomes by offering a more tolerable therapy option.
Restraint/Challenge
- Limited Awareness of Hepatitis Delta Virus (HDV)
Limited awareness of Hepatitis Delta Virus (HDV) infection is a significant restraint for the Middle East and Africa HDV infection market. Many healthcare providers and patients are not aware of the risks and consequences of HDV infection, leading to delayed diagnosis and treatment. This lack of awareness results in patients being diagnosed with liver disease at an advanced stage, making treatment more challenging and increasing the risk of complications and mortality.
- Side Effects of Current Treatments
Pegylated interferon-alpha has been a key therapeutic option for managing HDV due to its ability to induce a sustained viral response. However, its use is hampered by a range of debilitating side effects that can significantly impact patient adherence to the treatment regimen.
Common side effects of pegylated interferon-alpha include flu-like symptoms such as fever, chills, and muscle aches, as well as more severe issues such as fatigue, gastrointestinal disturbances, and psychological effects including depression and anxiety. These side effects can be distressing for patients, often leading to reduced quality of life and difficulty in maintaining consistent treatment. The severity of these adverse effects can discourage patients from completing their prescribed course of therapy, resulting in suboptimal treatment outcomes and potential disease progression.
Recent Developments
- In September 2024, Gilead Sciences, Inc. and Genesis Therapeutics have formed a strategic collaboration to discover and develop novel therapies using advanced AI-driven drug discovery technologies. This partnership aims to accelerate the creation of innovative treatments, enhancing Gilead's pipeline and strengthening its position in the competitive biopharma industry
- En mars 2024, Gilead Sciences Inc. a finalisé l'acquisition de CymaBay Therapeutics, ce qui lui a permis d'accéder à des thérapies innovantes pour les maladies du foie et les maladies rares. Cette acquisition élargit le portefeuille de recherche de Gilead et renforce son pipeline, améliorant ainsi sa capacité à répondre à des besoins médicaux non satisfaits. L'acquisition de CymaBay fournit à Gilead de nouveaux candidats médicaments prometteurs et une expertise dans le domaine des maladies du foie et des maladies rares, renforçant ainsi ses capacités de recherche et élargissant son offre thérapeutique
- En mars 2024, Gilead Sciences, Inc. et Merus ont annoncé une collaboration visant à découvrir de nouveaux anticorps engageant les cellules T trispécifiques, dans le but d'améliorer l' immunothérapie contre le cancer. Ce partenariat associe l'expertise de Gilead à la technologie innovante de Merus pour développer des traitements avancés contre le cancer
- En mars 2024, Alnylam Pharmaceuticals a lancé le Family Health History Road Trip pour promouvoir les discussions sur l'amylose héréditaire ATTR (hATTR). La généalogiste Bernice Bennett a parcouru le pays pour souligner l'importance des antécédents médicaux familiaux pour un diagnostic plus précoce
Portée du marché de l'infection par le virus de l'hépatite delta (VHD) au Moyen-Orient et en Afrique
Le marché de l'infection par le virus de l'hépatite delta (VHD) au Moyen-Orient et en Afrique est segmenté en neuf segments notables en fonction du type, du traitement, du type de médicament, de la voie d'administration, de la tranche d'âge, du sexe, de la transmission, de l'utilisateur final et du canal de distribution. La croissance entre les segments vous aide à analyser les niches de croissance et les stratégies pour aborder le marché et déterminer vos principaux domaines d'application et les différences entre vos marchés cibles.
Taper
- Hépatite D aiguë
- Hépatite D chronique
Sur la base du type, le marché est segmenté en hépatite D aiguë, hépatite D chronique.
Traitement
- Chirurgie (transplantation du foie)
- Médicament
En fonction du traitement, le marché est segmenté en chirurgie (transplantation du foie) et en médicaments.
Type de médicament
- De marque
- Générique
En fonction du type de médicament, le marché est segmenté en médicaments de marque et génériques.
Voie d'administration
- Oral
- Parentérale
Sur la base de la voie d’administration, le marché est segmenté en voie orale et parentérale.
Tranche d'âge
- Adultes
- Gériatrie
- Pédiatrique
Sur la base de la tranche d’âge, le marché est segmenté en adultes, gériatriques et pédiatriques.
Genre
- Femelle
- Mâle
Sur la base du sexe, le marché est segmenté en femmes et en hommes.
Transmission
- Aiguilles contaminées
- Exposition au sang infecté
- Transfusion de produits sanguins et plasmatiques
- Autres
Sur la base de la transmission, le marché est segmenté en aiguilles contaminées, exposition au sang infecté, transfusion de produits sanguins et plasmatiques et autres.
Utilisateur final
- Hôpitaux
- Cliniques spécialisées
- Cadre de soins à domicile
- Instituts de recherche et centres universitaires
- Centres de chirurgie ambulatoire
- Autres
Sur la base de l'utilisateur final, le marché est segmenté en hôpitaux, cliniques spécialisées, soins à domicile, instituts de recherche et centres universitaires, centres de chirurgie ambulatoire et autres.
Canal de distribution
- Appel d'offres direct
- Ventes au détail
- Autres
Sur la base du canal de distribution, le marché est segmenté en appels d'offres directs, ventes au détail et autres.
Analyse/perspectives régionales du marché de l'infection par le virus de l'hépatite delta (VHD) au Moyen-Orient et en Afrique
Le marché de l’infection par le virus de l’hépatite Delta (HDV) au Moyen-Orient et en Afrique est segmenté en neuf segments notables en fonction du type, du traitement, de la voie d’administration, de la forme posologique, du groupe d’âge, du sexe, de la transmission, de l’utilisateur final et du canal de distribution.
Les pays couverts dans ce rapport de marché sont l’Afrique du Sud, l’Arabie saoudite, les Émirats arabes unis, l’Égypte, Bahreïn, le Koweït, Oman, le Qatar et le reste du Moyen-Orient et de l’Afrique.
L'Arabie saoudite devrait dominer le marché de l'infection par l'hépatite Delta (HDV) au Moyen-Orient et en Afrique, en raison de sa forte prévalence de co-infection par le VHB et le VHD parmi la population locale, en particulier parmi les travailleurs immigrés en provenance de pays à forte prévalence du VHD, comme l'Asie et l'Afrique.
La section par pays du rapport fournit également des facteurs individuels ayant un impact sur le marché et des changements dans la réglementation du marché national qui ont un impact sur les tendances actuelles et futures du marché. Des points de données tels que les nouvelles ventes, les ventes de remplacement, la démographie du pays, les actes réglementaires et les tarifs d'importation et d'exportation sont quelques-uns des principaux indicateurs utilisés pour prévoir le scénario du marché pour les différents pays. En outre, la présence et la disponibilité de grandes entreprises de services et les défis auxquels elles sont confrontées en raison de la concurrence importante ou rare des acteurs locaux et nationaux et l'impact des canaux de vente sont pris en compte lors de l'analyse prévisionnelle des données nationales.
Analyse du paysage concurrentiel et des parts de marché de l'infection par le virus de l'hépatite Delta (VHD) au Moyen-Orient et en Afrique
Le paysage concurrentiel du marché de l'infection par l'hépatite Delta (HDV) au Moyen-Orient et en Afrique fournit des détails sur les concurrents. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements en R&D, les nouvelles initiatives du marché, les sites et installations de production, les forces et les faiblesses de l'entreprise, le lancement du produit, les approbations de produits, la largeur et l'étendue du produit, la domination des applications et la courbe de survie du type de produit. Les points de données ci-dessus fournis ne concernent que l'orientation de l'entreprise sur le marché.
Certains des principaux acteurs du marché opérant sur le marché sont Gilead Sciences, Inc., Genentech, Inc., Eiger BioPharmaceuticals, Johnson & Johnson Services, Inc., Assembly Biosciences, Inc., PharmaEssentia Corporation, Vir Biotechnology, Inc., Huahui Health Ltd., Replicor, GlobeImmune Inc. et Alnylam Pharmaceuticals, Inc. entre autres.
SKU-
Accédez en ligne au rapport sur le premier cloud mondial de veille économique
- Tableau de bord d'analyse de données interactif
- Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
- Accès d'analyste de recherche pour la personnalisation et les requêtes
- Analyse de la concurrence avec tableau de bord interactif
- Dernières actualités, mises à jour et analyse des tendances
- Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Table des matières
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET END USER COVERAGE GRID
2.8 DBMR MARKET POSITION GRID
2.9 VENDOR SHARE ANALYSIS
2.1 SECONDARY SOURCES
2.11 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTAL ANALYSIS
4.2 PORTER FIVE FORCES
4.3 MIDDLE EAST AND AFRICA CLINICAL TRIAL MARKET FOR MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET
4.4 DISTRIBUTION OF PRODUCTS BY PHASE
5 EPIDEMIOLOGY
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 GROWING PREVALENCE OF HEPATITIS
6.1.2 INCREASE IN HEALTHCARE EXPENDITURE
6.1.3 ONGOING RESEARCH AND DEVELOPMENT INITIATIVES
6.1.4 ADVANCES IN DIAGNOSTIC TECHNOLOGIES
6.2 RESTRAINTS
6.2.1 LIMITED AWARENESS OF HEPATITIS DELTA VIRUS (HDV)
6.2.2 HIGH COST OF TREATMENT
6.3 OPPORTUNITIES
6.3.1 RISING INNOVATIVE DRUG DEVELOPMENT
6.3.2 INCREASING DEVELOPMENT OF COMBINATION THERAPIES
6.3.3 GROWING ADVANCEMENTS IN DIGITAL HEALTH SOLUTIONS
6.4 CHALLENGES
6.4.1 SIDE EFFECTS OF CURRENT TREATMENTS
6.4.2 SLOW REGULATORY APPROVALS
7 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE
7.1 OVERVIEW
7.2 ACUTE HEPATITIS D
7.3 CHRONIC HEPATITIS D
8 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT
8.1 OVERVIEW
8.2 SURGERY (LIVER TRANSPLANT)
8.3 MEDICATION
8.3.1 APPROVED THERAPIES
8.3.1.1 PEGYLATED INTERFERON ALPHA
8.3.1.2 ENTRY INHIBITOR (BULEVIRTIDE)
8.3.2 EMERGING THERAPIES
9 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM
9.1 OVERVIEW
9.2 TABLET
9.3 CAPSULE
9.4 INJECTABLE
10 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE
10.1 OVERVIEW
10.2 BRANDED
10.3 GENERIC
11 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION
11.1 OVERVIEW
11.2 ORAL
11.2.1 TABLET
11.2.2 CAPSULE
11.2.3 OTHERS
11.3 PARENTERAL
12 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER
12.1 OVERVIEW
12.2 FEMALE
12.3 MALE
13 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP
13.1 OVERVIEW
13.2 ADULTS
13.3 GERIATRIC
13.4 PEDIATRIC
14 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION
14.1 OVERVIEW
14.2 CONTAMINATED NEEDLES
14.3 EXPOSURE TO INFECTED BLOOD
14.4 BLOOD AND PLASMA PRODUCT TRANSFUSION
14.5 OTHERS
15 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER
15.1 OVERVIEW
15.2 HOSPITALS
15.3 SPECIALTY CENTERS
15.4 HOME CARE SETTING
15.5 RESEARCH INSTITUTES & ACADEMIC CENTERS
15.6 AMBULATORY SURGICAL CENTERS
15.7 OTHERS
16 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL
16.1 OVERVIEW
16.2 DIRECT TENDER
16.3 RETAIL SALES
16.3.1 HOSPITAL PHARMACY
16.3.2 RETAIL PHARMACY
16.3.3 ONLINE PHARMACY
16.4 OTHERS
17 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION
17.1 MIDDLE EAST AND AFRICA
17.1.1 SAUDI ARABIA
17.1.2 SOUTH AFRICA
17.1.3 U.A.E
17.1.4 EGYPT
17.1.5 BAHRAIN
17.1.6 KUWAIT
17.1.7 OMAN
17.1.8 QATAR
17.1.9 REST OF MIDDLE EAST
18 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: COMPANY LANDSCAPE
18.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
19 SWOT ANALYSIS
20 COMPANY PROFILE
20.1 GILEAD SCIENCES, INC.
20.1.1 COMPANY SNAPSHOT
20.1.2 REVENUE ANALYSIS
20.1.3 COMPANY SHARE ANALYSIS
20.1.4 PIPELINE PRODUCT
20.1.5 RECENT DEVELOPMENTS
20.2 GENENTECH, INC.
20.2.1 COMPANY SNAPSHOT
20.2.2 PRODUCT PORTFOLIO
20.2.3 RECENT DEVELOPMENT
20.3 ALNYLAM PHARMACEUTICALS, INC.
20.3.1 COMPANY SNAPSHOT
20.3.2 REVENUE ANALYSIS
20.3.3 PIPELINE PRODUCT
20.3.4 RECENT DEVELOPMENTS
20.4 ASSEMBLY BIOSCIENCES, INC.
20.4.1 COMPANY SNAPSHOT
20.4.2 REVENUE ANALYSIS
20.4.3 PIPELINE PRODUCT
20.4.4 RECENT DEVELOPMENTS
20.5 EIGER BIOPHARMACEUTICALS
20.5.1 COMPANY SNAPSHOT
20.5.2 REVENUE ANALYSIS
20.5.3 COMPANY SHARE ANALYSIS
20.5.4 PRODUCT PORTFOLIO
20.5.5 PIPELINE PRODUCT
20.5.6 RECENT DEVELOPMENT
20.6 GLOBEIMMUNE INC.
20.6.1 COMPANY SNAPSHOT
20.6.2 PIPELINE PRODUCT
20.6.3 RECENT DEVELOPMENT
20.7 HUAHUI HEALTH LTD.
20.7.1 COMPANY SNAPSHOT
20.7.2 PIPELINE PRODUCT
20.7.3 RECENT DEVELOPMENT
20.8 JOHNSON & JOHNSON SERVICES, INC.
20.8.1 COMPANY SNAPSHOT
20.8.2 REVENUE ANALYSIS
20.8.3 PIPELINE PRODUCT
20.8.4 RECENT DEVELOPMENT
20.9 PHARMAESSENTIA CORPORATION
20.9.1 COMPANY SNAPSHOT
20.9.2 REVENUE ANALYSIS
20.9.3 PIPELINE PRODUCT
20.9.4 RECENT DEVELOPMENT
20.1 REPLICOR
20.10.1 COMPANY SNAPSHOT
20.10.2 PIPELINE PRODUCT
20.10.3 RECENT DEVELOPMENTS
20.11 VIR BIOTECHNOLOGY, INC.
20.11.1 COMPANY SNAPSHOT
20.11.2 REVENUE ANALAYSIS
20.11.3 PRODUCT PIPELINE
20.11.4 RECENT DEVELOPMENTS
21 QUESTIONNAIRE
22 RELATED REPORTS
Liste des tableaux
TABLE 1 EMERGING NOVEL THERAPIES FOR HDV
TABLE 2 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 3 MIDDLE EAST AND AFRICA ACUTE HEPATITIS D IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 4 MIDDLE EAST AND AFRICA CHRONIC HEPATITIS D IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 5 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 6 MIDDLE EAST AND AFRICA SURGERY (LIVER TRANSPLANT) IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 7 MIDDLE EAST AND AFRICA MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 8 MIDDLE EAST AND AFRICA MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 9 MIDDLE EAST AND AFRICA APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 10 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 11 MIDDLE EAST AND AFRICA TABLET IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 12 MIDDLE EAST AND AFRICA CAPSULE IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 13 MIDDLE EAST AND AFRICA INJECTABLE IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 14 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 15 MIDDLE EAST AND AFRICA BRANDED IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 16 MIDDLE EAST AND AFRICA GENERIC IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 17 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 18 MIDDLE EAST AND AFRICA ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 19 MIDDLE EAST AND AFRICA ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 20 MIDDLE EAST AND AFRICA PARENTERAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 21 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 22 MIDDLE EAST AND AFRICA FEMALE IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 23 MIDDLE EAST AND AFRICA MALE IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 24 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 25 MIDDLE EAST AND AFRICA ADULTS IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 26 MIDDLE EAST AND AFRICA GERIATRIC IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 27 MIDDLE EAST AND AFRICA PEDIATRIC IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 28 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)
TABLE 29 MIDDLE EAST AND AFRICA CONTAMINATED NEEDLES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 30 MIDDLE EAST AND AFRICA EXPOSURE TO INFECTED BLOOD IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 31 MIDDLE EAST AND AFRICA BLOOD AND PLASMA PRODUCT TRANSFUSION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 32 MIDDLE EAST AND AFRICA OTHERS IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 33 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 34 MIDDLE EAST AND AFRICA HOSPITALS IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 35 MIDDLE EAST AND AFRICA SPECIALTY CLINICS IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 36 MIDDLE EAST AND AFRICA HOME CARE SETTING IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 37 MIDDLE EAST AND AFRICA RESEARCH INSTITUTES AND ACADEMIC CENTERS IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 38 MIDDLE EAST AND AFRICA AMBULATORY SURGICAL CENTERS IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 39 MIDDLE EAST AND AFRICA OTHERS IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 40 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 41 MIDDLE EAST AND AFRICA DIRECT TENDER IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 42 MIDDLE EAST AND AFRICA RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 43 MIDDLE EAST AND AFRICA RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 44 MIDDLE EAST AND AFRICA OTHERS IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 45 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 46 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)
TABLE 47 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 48 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 49 MIDDLE EAST AND AFRICA MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 50 MIDDLE EAST AND AFRICA APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 51 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 52 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 53 MIDDLE EAST AND AFRICA ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 54 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 55 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 56 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 57 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)
TABLE 58 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 59 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 60 MIDDLE EAST AND AFRICA RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 61 SAUDI ARABIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 62 SAUDI ARABIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 63 SAUDI ARABIA MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 64 SAUDI ARABIA APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 65 SAUDI ARABIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 66 SAUDI ARABIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 67 SAUDI ARABIA ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 68 SAUDI ARABIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 69 SAUDI ARABIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 70 SAUDI ARABIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 71 SAUDI ARABIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)
TABLE 72 SAUDI ARABIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 73 SAUDI ARABIA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 74 SAUDI ARABIA RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 75 SOUTH AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 76 SOUTH AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 77 SOUTH AFRICA MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 78 SOUTH AFRICA APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 79 SOUTH AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 80 SOUTH AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 81 SOUTH AFRICA ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 82 SOUTH AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 83 SOUTH AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 84 SOUTH AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 85 SOUTH AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)
TABLE 86 SOUTH AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 87 SOUTH AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 88 SOUTH AFRICA RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 80 U.A.E HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 90 U.A.E HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 91 U.A.E MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 92 U.A.E APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 93 U.A.E HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 94 U.A.E HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 95 U.A.E ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 96 U.A.E HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 97 U.A.E HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 98 U.A.E HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 99 U.A.E HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)
TABLE 100 U.A.E HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 101 U.A.E HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 102 U.A.E RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 103 EGYPT HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 104 EGYPT HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 105 EGYPT MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 106 EGYPT APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 107 EGYPT HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 108 EGYPT HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 109 EGYPT ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 110 EGYPT HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 111 EGYPT HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 112 EGYPT HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 113 EGYPT HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)
TABLE 114 EGYPT HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 115 EGYPT HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 116 EGYPT RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 117 BAHRAIN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 118 BAHRAIN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 119 BAHRAIN MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 120 BAHRAIN APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 121 BAHRAIN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 122 BAHRAIN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 123 BAHRAIN ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 124 BAHRAIN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 125 BAHRAIN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 126 BAHRAIN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 127 BAHRAIN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)
TABLE 128 BAHRAIN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 129 BAHRAIN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 130 BAHRAIN RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 131 KUWAIT HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 132 KUWAIT HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 133 KUWAIT MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 134 KUWAIT APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 135 KUWAIT HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 136 KUWAIT HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 137 KUWAIT ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 138 KUWAIT HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 139 KUWAIT HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 140 KUWAIT HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 141 KUWAIT HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)
TABLE 142 KUWAIT HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 143 KUWAIT HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 144 KUWAIT RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 145 OMAN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 146 OMAN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 147 OMAN MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 148 OMAN APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 149 OMAN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 150 OMAN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 151 OMAN ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 152 OMAN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 153 OMAN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 154 OMAN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 155 OMAN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)
TABLE 156 OMAN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 157 OMAN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 158 OMAN RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 159 QATAR HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 160 QATAR HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 161 QATAR MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 162 QATAR APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 163 QATAR HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 164 QATAR HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 165 QATAR ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 166 QATAR HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 167 QATAR HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 168 QATAR HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 169 QATAR HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)
TABLE 170 QATAR HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 171 QATAR HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 172 QATAR RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 173 REST OF MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
Liste des figures
FIGURE 1 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: MIDDLE EAST AND AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: MARKET END USER COVERAGE GRID
FIGURE 8 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: DBMR MARKET POSITION GRID
FIGURE 9 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: SEGMENTATION
FIGURE 11 TWO SEGMENTS COMPRISE THE MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE
FIGURE 12 GROWING PREVALENCE OF HEPATITIS IS DRIVING THE GROWTH OF THE MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET FROM 2024 TO 2031
FIGURE 13 THE TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET IN 2024 AND 2031
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET
FIGURE 15 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY TYPE, 2023
FIGURE 16 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY TYPE, 2024-2031 (USD THOUSAND)
FIGURE 17 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY TYPE, CAGR (2024-2031)
FIGURE 18 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY TYPE, LIFELINE CURVE
FIGURE 19 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY TREATMENT, 2023
FIGURE 20 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY TREATMENT, 2024-2031 (USD THOUSAND)
FIGURE 21 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY TREATMENT, CAGR (2024-2031)
FIGURE 22 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY TREATMENT, LIFELINE CURVE
FIGURE 23 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY DOSAGE FORM, 2023
FIGURE 24 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY DOSAGE FORM, 2024-2031 (USD THOUSAND)
FIGURE 25 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY DOSAGE FORM, CAGR (2024-2031)
FIGURE 26 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY DOSAGE FORM, LIFELINE CURVE
FIGURE 27 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY DRUG TYPE, 2023
FIGURE 28 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY DRUG TYPE, 2024-2031 (USD THOUSAND)
FIGURE 29 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY DRUG TYPE, CAGR (2024-2031)
FIGURE 30 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 31 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY ROUTE OF ADMINISTRATION, 2023
FIGURE 32 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY ROUTE OF ADMINISTRATION, 2024-2031 (USD THOUSAND)
FIGURE 33 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2024-2031)
FIGURE 34 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 35 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY GENDER,2023
FIGURE 36 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY GENDER, 2024-2031 (USD THOUSAND)
FIGURE 37 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY GENDER, CAGR (2024-2031)
FIGURE 38 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY GENDER, LIFELINE CURVE
FIGURE 39 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY AGE GROUP, 2023
FIGURE 40 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY AGE GROUP, 2024-2031 (USD THOUSAND)
FIGURE 41 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY AGE GROUP, CAGR (2024-2031)
FIGURE 42 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY AGE GROUP, LIFELINE CURVE
FIGURE 43 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY TRANSMISSION, 2023
FIGURE 44 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY TRANSMISSION, 2024-2031 (USD THOUSAND)
FIGURE 45 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY TRANSMISSION, CAGR (2024-2031)
FIGURE 46 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY TRANSMISSION, LIFELINE CURVE
FIGURE 47 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY END USER, 2023
FIGURE 48 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY END USER, 2024-2031 (USD THOUSAND)
FIGURE 49 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY END USER, CAGR (2024-2031)
FIGURE 50 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY END USER, LIFELINE CURVE
FIGURE 51 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY DISTRIBUTION CHANNEL, 2023
FIGURE 52 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD THOUSAND)
FIGURE 53 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)
FIGURE 54 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 55 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: SNAPSHOT (2023)
FIGURE 56 MIDDLE EAST AND AFRICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: COMPANY SHARE 2023 (%)
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.
La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.
Personnalisation disponible
Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.
